Navigation Links
Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
Date:11/20/2009

NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Comprehensive Forecasts and Detailed Budget Benchmarks new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.

Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever.

At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.

Uncover Oncology Threats and Opportunities

Equip your teams with the most comprehensive forecast of the oncology marketplace -- from today's stalwarts to tomorrow's blockbusters.

Product Breakdown

112 Anti-cancer drugs in all major classes

15 Adjuncts

Product Profile Components

-Product history

-Competitive and strategic positioning

-Market growth opportunities

-Sales history and projections

-Drug's materiality to company

Budget Brand Resources for Development and Launch

Track real brand spending from the pre-clinical period through the first year on the market

Brand Spending Benchmarks

-Advertising and promotion

-Medical affairs

-Decision support (market research)

-Market access

    Summary

    Brand Spending Benchmarks

    Average brand spending by budget category:

    - Advertising and promotion

    - Medical affairs

    - Decision support (market research)

    - Market access

    Average brand spending by development stage:

    - Pre-Clinical to phase 2

    - Phase 3a

    - Phase 3b

    - First year on the market

    Product Profiles by Class

    Brand Information

    - Brand and generic name

    - Drug class

    - Delivery mechanism

    - Line of treatment

    Sales Data

    - Historical/current sales

    - Forecasted sales

    Approved Indications

    - Current Product Development Phases

    - Competitive and Strategic Positioning

    - Market Opportunities and Brand Growth

    - Patent, Generic and Litigation Information

    Oncology Indication Analysis

    - Current sales, major drugs and important companies

    - Forecasted sales and assessment of future drugs and market players

    - Pipeline development status

    - Major market events, changes in treatments, patent expirations, etc.

    Companies' Oncology Portfolios

    - Current sales, major drugs and important companies

    - Forecasted sales and assessment of future drugs and market players

    - Pipeline development status

    Companies mentioned

    Amgen AstraZeneca Bristol-Myers Squibb Celgene Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Roche and Genentech Sanofi-Aventis Schering-Plough

    To order this report:

    Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

    http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

    More market research reports here!

    
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626
    
    
    
    
    

    SOURCE Reportlinker


    '/>"/>

SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds Biologic Imaging Reagents: Technologies and Global Markets Report
2. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
3. Reportlinker Adds Markets for Advanced Wound Care Technologies Report
4. Reportlinker Adds Antiseptics and Disinfectants Report
5. Reportlinker Adds Commercial Amino Acids Report
6. Reportlinker Adds Membrane & Separation Technology News Review, 2008 Report
7. Reportlinker Adds the Dental Market: Techniques, Equipment and Materials Report
8. Reportlinker Adds Pediatric Health Care Products and Services Report
9. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
10. Reportlinker Adds 2008/2009 Healthcare Research Review Report
11. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: